ProKidney Corp Valuation
| PROK Stock | USD 0.99 0.02 2.06% |
Today, the company appears to be overvalued. ProKidney Corp holds a recent Real Value of $0.95 per share. The prevailing price of the company is $0.99. Our model determines the value of ProKidney Corp from analyzing the company fundamentals such as Current Valuation of (230.98 M), return on equity of -0.41, and Shares Owned By Insiders of 27.16 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that ProKidney Corp's price fluctuation is extremely dangerous at this time. Calculation of the real value of ProKidney Corp is based on 3 months time horizon. Increasing ProKidney Corp's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ProKidney Corp's intrinsic value may or may not be the same as its current market price of 0.99, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.99 | Real 0.95 | Hype 0.99 | Naive 1.17 |
The intrinsic value of ProKidney Corp's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence ProKidney Corp's stock price.
Estimating the potential upside or downside of ProKidney Corp helps investors to forecast how ProKidney stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ProKidney Corp more accurately as focusing exclusively on ProKidney Corp's fundamentals will not take into account other important factors: ProKidney Corp Total Value Analysis
ProKidney Corp is at this time estimated to have valuation of (230.98 M) with market capitalization of 1.85 B, debt of 2.47 M, and cash on hands of 21.88 M. The negative valuation of ProKidney Corp may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the ProKidney Corp fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(230.98 M) | 1.85 B | 2.47 M | 21.88 M |
ProKidney Corp Investor Information
About 27.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.62. ProKidney Corp had not issued any dividends in recent years. The entity had 1:1 split on the 12th of July 2022. Based on the analysis of ProKidney Corp's profitability, liquidity, and operating efficiency, ProKidney Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.ProKidney Corp Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ProKidney Corp has an asset utilization ratio of 0.0172 percent. This suggests that the Company is making $1.72E-4 for each dollar of assets. An increasing asset utilization means that ProKidney Corp is more efficient with each dollar of assets it utilizes for everyday operations.ProKidney Corp Ownership Allocation
ProKidney Corp owns a total of 127.97 Million outstanding shares. ProKidney Corp has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.ProKidney Corp Profitability Analysis
The company reported the previous year's revenue of 76 K. Net Loss for the year was (163.34 M) with profit before overhead, payroll, taxes, and interest of 76 K.About ProKidney Corp Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of ProKidney Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of ProKidney Corp based exclusively on its fundamental and basic technical indicators. By analyzing ProKidney Corp's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of ProKidney Corp's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of ProKidney Corp. We calculate exposure to ProKidney Corp's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ProKidney Corp's related companies.ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Prokidney Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
ProKidney Corp Growth Indicators
Investing in growth stocks can be very risky. If the company such as ProKidney Corp does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 126.2 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.